Paromomycin sulfate

Paromomycin sulfate (brand name Humatin) is a drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005 and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.